$HAE
HAEMONETICS CORP

2021 Q3 Form 10-Q Financial Statement

#000031314321000045 Filed on August 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q2
Revenue $228.5M $195.6M
YoY Change 9.09% -17.98%
Cost Of Revenue $120.4M $105.5M
YoY Change 16.1% -13.87%
Gross Profit $108.1M $90.03M
YoY Change 2.21% -22.32%
Gross Profit Margin 47.3% 46.03%
Selling, General & Admin $91.22M $62.30M
YoY Change 43.49% -14.65%
% of Gross Profit 84.39% 69.2%
Research & Development $12.70M $7.750M
YoY Change 87.8% 3.51%
% of Gross Profit 11.75% 8.61%
Depreciation & Amortization $25.03M $20.70M
YoY Change 19.78% -24.45%
% of Gross Profit 23.16% 22.99%
Operating Expenses $106.7M $78.32M
YoY Change 127.19% -39.39%
Operating Profit $1.390M $11.72M
YoY Change -97.64% -188.07%
Interest Expense -$4.398M -$3.700M
YoY Change 15.74% -15.91%
% of Operating Profit -316.4% -31.58%
Other Income/Expense, Net -$4.398M -$3.735M
YoY Change 14.95% -15.56%
Pretax Income -$3.008M $7.980M
YoY Change -105.47% -145.02%
Income Tax $1.400M -$2.500M
% Of Pretax Income -31.33%
Net Earnings -$4.454M $10.53M
YoY Change -109.26% -224.15%
Net Earnings / Revenue -1.95% 5.38%
Basic Earnings Per Share -$0.09 $0.21
Diluted Earnings Per Share -$0.09 $0.21
COMMON SHARES
Basic Shares Outstanding 50.94M shares 50.42M shares
Diluted Shares Outstanding 50.94M shares 51.25M shares

Balance Sheet

Concept 2021 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.5M $275.7M
YoY Change -37.87% 44.95%
Cash & Equivalents $173.5M $275.7M
Short-Term Investments
Other Short-Term Assets $51.50M $48.10M
YoY Change 49.7% 20.85%
Inventory $326.5M $294.5M
Prepaid Expenses
Receivables $132.9M $141.1M
Other Receivables $0.00 $0.00
Total Short-Term Assets $684.4M $759.4M
YoY Change -9.98% 23.43%
LONG-TERM ASSETS
Property, Plant & Equipment $214.8M $243.0M
YoY Change -10.66% -12.21%
Goodwill $466.3M $217.3M
YoY Change 117.3% 2.92%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $68.84M $71.89M
YoY Change -3.56% 128.35%
Total Long-Term Assets $1.110B $673.8M
YoY Change 68.69% 4.57%
TOTAL ASSETS
Total Short-Term Assets $684.4M $759.4M
Total Long-Term Assets $1.110B $673.8M
Total Assets $1.794B $1.433B
YoY Change 26.51% 13.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $49.13M $48.46M
YoY Change 0.12% -20.29%
Accrued Expenses $34.37M $36.40M
YoY Change 17.71% 15.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $17.03M $231.4M
YoY Change -89.81% 96.83%
Total Short-Term Liabilities $228.3M $407.8M
YoY Change -32.56% 38.87%
LONG-TERM LIABILITIES
Long-Term Debt $767.3M $296.9M
YoY Change 158.35% -6.68%
Other Long-Term Liabilities $97.15M $106.8M
YoY Change -6.76% 149.29%
Total Long-Term Liabilities $864.5M $403.7M
YoY Change 115.47% 11.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $228.3M $407.8M
Total Long-Term Liabilities $864.5M $403.7M
Total Liabilities $1.093B $811.5M
YoY Change 47.73% 23.96%
SHAREHOLDERS EQUITY
Retained Earnings $154.6M $89.04M
YoY Change 12.7% -10.44%
Common Stock $551.6M $563.2M
YoY Change -3.1% 7.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $677.1M $608.6M
YoY Change
Total Liabilities & Shareholders Equity $1.794B $1.433B
YoY Change 26.51% 13.78%

Cashflow Statement

Concept 2021 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$4.454M $10.53M
YoY Change -109.26% -224.15%
Depreciation, Depletion And Amortization $25.03M $20.70M
YoY Change 19.78% -24.45%
Cash From Operating Activities -$1.680M $11.81M
YoY Change -105.75% 349.47%
INVESTING ACTIVITIES
Capital Expenditures $13.92M $7.696M
YoY Change -267.7% -6.7%
Acquisitions $2.500M $16.61M
YoY Change
Other Investing Activities -$1.932M -$16.20M
YoY Change -104.25% -260.4%
Cash From Investing Activities -$15.85M -$23.90M
YoY Change -142.73% -1384.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $4.375M $4.375M
YoY Change 0.0%
Cash From Financing Activities -$1.634M $149.0M
YoY Change -97.46% 825.74%
NET CHANGE
Cash From Operating Activities -$1.680M $11.81M
Cash From Investing Activities -$15.85M -$23.90M
Cash From Financing Activities -$1.634M $149.0M
Net Change In Cash -$18.84M $138.4M
YoY Change -1091.74% 562.81%
FREE CASH FLOW
Cash From Operating Activities -$1.680M $11.81M
Capital Expenditures $13.92M $7.696M
Free Cash Flow -$15.60M $4.116M
YoY Change -141.6% -173.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000313143
CY2021Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-02
CY2021Q3 dei Amendment Flag
AmendmentFlag
false
CY2021Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2236000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2226000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
335060000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
320640000 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51012969 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50868820 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51012969 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50868820 shares
CY2021Q3 dei Document Type
DocumentType
10-Q
CY2021Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 dei Document Period End Date
DocumentPeriodEndDate
2021-07-03
CY2021Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q3 dei Entity File Number
EntityFileNumber
001-14041
CY2021Q3 dei Entity Registrant Name
EntityRegistrantName
HAEMONETICS CORP
CY2021Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2021Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2882273
CY2021Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
125 Summer Street
CY2021Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston,
CY2021Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
CY2021Q3 dei City Area Code
CityAreaCode
781
CY2021Q3 dei Local Phone Number
LocalPhoneNumber
848-7100
CY2021Q3 dei Security12b Title
Security12bTitle
Common stock, $.01 par value per share
CY2021Q3 dei Trading Symbol
TradingSymbol
HAE
CY2021Q3 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q3 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q3 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q3 dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51029618 shares
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
228528000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195577000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
120443000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
105547000 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
108085000 USD
CY2020Q2 us-gaap Gross Profit
GrossProfit
90030000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12701000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7750000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91218000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
62302000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12379000 USD
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8263000 USD
CY2021Q3 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
9603000 USD
CY2020Q2 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
0 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
106695000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
78315000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1390000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
11715000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4398000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3735000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3008000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
7980000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1446000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2547000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50939000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50418000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50939000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51247000 shares
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4007000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11956000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173462000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192305000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
132908000 USD
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
127555000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
326500000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
322614000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
684368000 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
693546000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51498000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51072000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
214782000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217559000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
353688000 USD
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
365483000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
466314000 USD
CY2021Q2 us-gaap Goodwill
Goodwill
466444000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6197000 USD
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
6009000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68838000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
70882000 USD
CY2021Q3 us-gaap Assets
Assets
1794187000 USD
CY2021Q2 us-gaap Assets
Assets
1819923000 USD
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
17025000 USD
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
17016000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
49131000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
50293000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
34372000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
47600000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
127811000 USD
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
138586000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
228339000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
253495000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
767345000 USD
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
690592000 USD
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
24278000 USD
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
43825000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
97145000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100341000 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
510000 USD
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
509000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
551108000 USD
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
602727000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
154562000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
157981000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29100000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29547000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
677080000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
731670000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1794187000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1819923000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
731670000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2210000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6828000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
447000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
677080000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
587109000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2144000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1193000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6167000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1429000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
608569000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25033000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
20724000 USD
CY2021Q3 hae Amortization Of Fair Value Inventory Step Up
AmortizationOfFairValueInventoryStepUp
5295000 USD
CY2020Q2 hae Amortization Of Fair Value Inventory Step Up
AmortizationOfFairValueInventoryStepUp
0 USD
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
5144000 USD
CY2020Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1028000 USD
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
6828000 USD
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
6167000 USD
CY2021Q3 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
1019000 USD
CY2020Q2 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
147000 USD
CY2021Q3 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-544000 USD
CY2020Q2 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
1452000 USD
CY2021Q3 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
9603000 USD
CY2020Q2 hae Gain Loss On Divestiture And Sale Of Assets
GainLossOnDivestitureAndSaleOfAssets
0 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
9774000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2021Q3 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-355000 USD
CY2020Q2 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-841000 USD
CY2021Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5342000 USD
CY2020Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-25067000 USD
CY2021Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8553000 USD
CY2020Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24557000 USD
CY2021Q3 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-2121000 USD
CY2020Q2 us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
3544000 USD
CY2021Q3 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1256000 USD
CY2020Q2 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-865000 USD
CY2021Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-29299000 USD
CY2020Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-25223000 USD
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1680000 USD
CY2020Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11812000 USD
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13919000 USD
CY2020Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7696000 USD
CY2021Q3 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2500000 USD
CY2020Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
406000 USD
CY2020Q2 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16606000 USD
CY2021Q3 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2020Q2 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 USD
CY2021Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
568000 USD
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15851000 USD
CY2020Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23896000 USD
CY2021Q3 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
0 USD
CY2020Q2 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
150000000 USD
CY2021Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4375000 USD
CY2020Q2 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4375000 USD
CY2021Q3 us-gaap Employee Stock Ownership Plan Esop Cash Contributions To Esop
EmployeeStockOwnershipPlanESOPCashContributionsToESOP
2210000 USD
CY2020Q2 us-gaap Employee Stock Ownership Plan Esop Cash Contributions To Esop
EmployeeStockOwnershipPlanESOPCashContributionsToESOP
2144000 USD
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
500000 USD
CY2020Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1193000 USD
CY2021Q3 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
31000 USD
CY2020Q2 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-11000 USD
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1634000 USD
CY2020Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
148951000 USD
CY2021Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
322000 USD
CY2020Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1547000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18843000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
138414000 USD
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192305000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137311000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173462000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275725000 USD
CY2021Q3 us-gaap Interest Paid Net
InterestPaidNet
1482000 USD
CY2020Q2 us-gaap Interest Paid Net
InterestPaidNet
2780000 USD
CY2021Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14494000 USD
CY2020Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2063000 USD
CY2021Q3 hae Transfers From Inventory To Fixed Assets
TransfersFromInventoryToFixedAssets
3203000 USD
CY2020Q2 hae Transfers From Inventory To Fixed Assets
TransfersFromInventoryToFixedAssets
2364000 USD
CY2021Q2 us-gaap Restructuring Reserve
RestructuringReserve
1012000 USD
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
3420000 USD
CY2021Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
63000 USD
CY2021Q3 us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
11000 USD
CY2021Q3 us-gaap Restructuring Reserve
RestructuringReserve
4380000 USD
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
3420000 USD
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
1065000 USD
CY2021Q3 us-gaap Restructuring Reserve
RestructuringReserve
4400000 USD
CY2021Q3 hae Restructuring Charges Payable In Next Twelve Months
RestructuringChargesPayableInNextTwelveMonths
3900000 USD
CY2021Q3 us-gaap Restructuring Charges
RestructuringCharges
3420000 USD
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
1065000 USD
CY2021Q3 hae Restructuring Related Costs
RestructuringRelatedCosts
6635000 USD
CY2020Q2 hae Restructuring Related Costs
RestructuringRelatedCosts
2935000 USD
CY2021Q3 hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
10055000 USD
CY2020Q2 hae Restructuringand Restructuring Related Costs
RestructuringandRestructuringRelatedCosts
4000000 USD
CY2021Q3 us-gaap Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed
BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
200000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1400000 USD
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.481
CY2021Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
800000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2500000 USD
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.319
CY2020Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-4000000.0 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50939000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50418000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4454000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
10527000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50939000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50418000 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2020Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
829000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50939000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51247000 shares
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000 shares
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
18400000 USD
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.69
CY2021Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4800000 USD
CY2021Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4800000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
24200000 USD
CY2021Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
20900000 USD
CY2021Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8600000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
75278000 USD
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74910000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
26562000 USD
CY2021Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23111000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
224660000 USD
CY2020Q2 hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
-3105000 USD
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
224593000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
326500000 USD
CY2021Q2 us-gaap Inventory Net
InventoryNet
322614000 USD
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2226000 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3824000 USD
CY2021Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-27000 USD
CY2020Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
259000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
17000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
119000 USD
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2236000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3446000 USD
CY2021Q3 hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
221146000 USD
CY2020Q2 hae Net Revenues Before Foreign Exchange Impact
NetRevenuesBeforeForeignExchangeImpact
193600000 USD
CY2021Q3 hae Effectof Exchange Rateon Revenues
EffectofExchangeRateonRevenues
2114000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
228528000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195577000 USD
CY2021Q3 hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
5812000 USD
CY2020Q2 hae Effectof Exchange Rateson Operating Income
EffectofExchangeRatesonOperatingIncome
711000 USD
CY2021Q3 hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
16733000 USD
CY2020Q2 hae Operating Expenses Transaction Costs
OperatingExpensesTransactionCosts
1290000 USD
CY2021Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
12379000 USD
CY2020Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
8263000 USD
CY2021Q3 hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
10055000 USD
CY2020Q2 hae Restructuringand Turnaround Costs
RestructuringandTurnaroundCosts
4000000 USD
CY2021Q3 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
3643000 USD
CY2020Q2 us-gaap Restructuring Reserve Accelerated Depreciation
RestructuringReserveAcceleratedDepreciation
2506000 USD
CY2021Q3 hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
2371000 USD
CY2020Q2 hae European Medical Device Regulation Costs
EuropeanMedicalDeviceRegulationCosts
753000 USD
CY2021Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
938000 USD
CY2020Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 USD
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
9603000 USD
CY2020Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1390000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
11715000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
228528000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195577000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
228528000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
195577000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29547000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-354000 USD
CY2021Q3 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-801000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
447000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29100000 USD

Files In Submission

Name View Source Status
0000313143-21-000045-index-headers.html Edgar Link pending
0000313143-21-000045-index.html Edgar Link pending
0000313143-21-000045.txt Edgar Link pending
0000313143-21-000045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hae-20210703.htm Edgar Link pending
hae-20210703.xsd Edgar Link pending
hae-20210703_cal.xml Edgar Link unprocessable
hae-20210703_def.xml Edgar Link unprocessable
hae-20210703_htm.xml Edgar Link completed
hae-20210703_lab.xml Edgar Link unprocessable
hae-20210703_pre.xml Edgar Link unprocessable
haeq1jun2022ex311.htm Edgar Link pending
haeq1jun2022ex312.htm Edgar Link pending
haeq1jun2022ex321.htm Edgar Link pending
haeq1jun2022ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending